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Abstract  
This is a narrative review of largely randomized trials on the impacts of probiotics. It 
concludes that evidence for beneficial effects of selected probiotics in the prevention of 
gastrointestinal disorders is limited mainly to acute gastroenteritis, antibiotic-associated 
diarrhea, infantile colic and necrotizing enterocolitis.  However, there is no broad 
consensus to recommend the use of probiotics in the prevention of these conditions, 
mainly because of the different designs used in different studies, resulting in limited 
evidence for specific strains, dosages and indications. More well-designed studies utilizing 
standardized methodologies are needed before recommendations can be proposed. At 
this stage, there is insufficient evidence to recommend the routine use of probiotics in 
infants and children for the prevention of gastro-intestinal disorders. 
Key points: 
Data indicate that selected probiotic strains are likely to prevent acute gastroenteritis, 
antibiotic-associated diarrhea, infantile colic and necrotizing enterocolitis. 
• However, relevant studies differ in design. 
• As a consequence, there is insufficient evidence for a global recommendation. 
• Since adverse effects are extremely rare, one might also recommend these products 
that were shown beneficial in the above mentioned indications, considering that patients 
may only profit since "there is  no harm and since there may be some benefit." 
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Introduction 
The microbiome is the totality of all the microbial 
cells that colonize the human body and their genes. 
The microbiota genes are far more predominant than 
the human genome.1 A balanced microbiome is 
associated with eubiosis and health, while an 
unbalanced microbiome or dysbiosis is related to 
health problems, within and outside the gastro-
intestinal (GI) tract. A lot of research is done on how 
to manipulate the gut microbiome to treat disease 
and improve human health. Diarrheal illness is the 
main one examined; it is the second leading cause of 
mortality among children younger than five years 
worldwide, causing an estimated 1.5 to 2 million 
deaths annually.  On average, every child under the 
age of 3 years is reported to develop at least one 
episode of infectious gastroenteritis per year.2  
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The gut microbiota can be altered by medications 
such as antibiotics and proton pump inhibitors, but 
also by probiotic supplements. Probiotics are live 
microorganisms, which when administered in 
adequate amounts, confer a health benefit on the 
host.3 While some authors have published strong 
evidence to support general effects of probiotics as 
a group rather than focusing on strain specific 
effects, others question this approach and yet 
conclude that there is insufficient evidence to guide 
the selection of the most effective strains for any 
specific purpose.4-6 The aim of this review was to 
review recent literature regarding the evidence for a 
health benefit of probiotic administration in the 
prevention of GI disease in infants and children.  
 
Search strategy and selection criteria 
 
The following data-bases were searched for 
randomized controlled trials between Jan 1, 2000 
and April 30, 2019: The Cochrane Library, 
MEDLINE, and EMBASE.  Search terms used 
were: "probiotics" and/or “prevention” and/or 
“prophylaxis” and/or “prophylactic use” and 
“gastrointestinal disorder” and/or “gastrointestinal 
disease” and “infant” and/or “child” and/or 
“pediatric”. Languages selected were “English”. 
 
Probiotics and prevention of diarrhea 
 
Acute gastroenteritis 
Acute gastroenteritis (AGE) is one of the most 
frequent infectious diseases during early childhood. 
The effect of the administration of probiotics has 
been tested in the prevention of AGE.   
In a RCT carried out in residential care 
settings, Bifidobacterium (B.) lactis Bb 12, when 
added to an acidified infant formula, was shown to 
have some, albeit very modest, protective effect 
against acute diarrhea in healthy children (Table 1).7 
The difference in the incidence of diarrhea during 
the study was not statistically different in the 
probiotic supplemented and control group (28.3 vs 
38.7%). The number of days with diarrhea did not 
differ between the groups. Feeding infants with the 
B. lactis BB12 reduced the risk of getting diarrhea 
by a factor of 1.9.7 In another RCT, B. animalis 
subsp. lactis BB-12 given over a period of 3 months 
had no preventive effect on GI and respiratory tract 
infections in healthy children who attend day care 
centers. Overall, the impact on the incidence of 
diarrhea was not significant.8 In a community based 
double-masked, randomized controlled trial in India 
of children 1-3 years of age who were randomly 
allocated to receive either control milk or the same 
milk fortified with 2.4 g/day of prebiotic 
oligosaccharide and 1.9x107 CFU/day of the 
probiotic B. lactis HN019, there was a significant 
reduction in dysentery, respiratory morbidity, and 
febrile illness.9 In another RCT, daily administration 
of a combination of B. animalis subsp lactis BB12 
and Lactobacillus (L) rhamnosus GG (LGG) for 6 
months in healthy infants did not reduce the number 
of episodes of diarrhea, or the number of days the 
child was absent from child care.10 In a multicenter 
trial, infant formulae containing B. lactis  and 
galacto- and fructo-oligosaccharides (GOS/FOS) 
did not reduce infection rates compared to formulas 
with only B. lactis.11 
A placebo-controlled trial with LGG showed 
a decreased incidence of diarrhea in undernourished 
formula-fed children in Peru, but not in breastfed 
children.12 It is tempting to hypothesize that the 
difference in GI microbiota development in 
breastfed vs formula fed infants may in part explain 
this observation. But breastmilk is also a source of 
protective IgA antibodies,13 which might protect the 
infant from developing infectious diarrhea.   
Outcomes in prevention may differ from 
outcomes in treatment, since two recent therapeutic 
trials concluded that probiotics (a mixture of L. 
rhamnosus R0011 and L. helveticus R0052, and 
LGG) did not shorten the duration of acute 
gastroenteritis.14,15 
The incidence of diarrhea was significantly 
reduced with a fermented milk supplement 
containing L. casei DN-114 001 (15.9%) compared 
with yoghurt (22.0%).16 Child care infants fed a 
formula supplemented with L. reuteri (American 
Type Culture Collection 55730) or B. lactis BB 12 
had fewer and shorter episodes of diarrhea than 
children fed regular formula, with no effect on 
respiratory illnesses.17  Healthy children attending 
day care centers, with daily administration of L. 
reuteri DSM 17938 showed a significant effect in 
reduced episodes and durations of diarrhea and 
respiratory tract infection compared to placebo, with 
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consequent cost savings for the community [18]. 
The number of doctor visits, antibiotic use, 
absenteeism from day school and parental 
absenteeism from work were significantly reduced 
in the L. reuteri group (P < .05).18 According to a 
review,  L. reuteri is reported to be effective in 
reducing the incidence of diarrhea in children 
attending day care centers.19  
Should administration of probiotics to 
prevent AGE be recommended? Evidence from 
literature is limited and differs in design, strains 
administered, and outcomes measured. Preventive 
administration of some specific probiotic strains 
seems to decrease the incidence of AGE--although 
there are also negative trials7,8 in regions with a very 
high incidence of the condition. 
 
Nosocomial diarrhea 
 
In 1994, the first report that showed a benefit of 
supplementation of infant formula with B. bifidum 
and Streptococcus thermophilus in reducing the 
incidence of acute diarrhea and rotavirus shedding 
in infants admitted to a chronic medical care hospital 
(Table 2) was published by Saavedra et al.20 In 
contrast, B.  animalis subsp. lactis BB12 was not 
effective in preventing nosocomial infections when 
given to children of more than 1 year during an acute 
hospitalization.21 
Data regarding LGG are contradictory. 
Prophylactic use of LGG was shown significantly to 
reduce the risk of nosocomial diarrhea in infants, 
particularly nosocomial rotavirus gastroenteritis, 
resulting in a number needed to treat of 4.22 
However, formula supplementation with LGG 
appeared ineffective in preventing nosocomial 
rotavirus infections, whereas breastfeeding was 
effective.23 A randomized controlled trial showed 
that LGG (6×109 colony forming units (CFU)/day) 
together with vitamins B and C and zinc given for 
15 days, starting on the first day of hospitalization, 
to children ranging from 0.5-5.0 years of age 
resulted in a reduced incidence of nosocomial 
infections.24  
According to a review, administration of 
LGG and B. bifidum and Streptococcus 
thermophilus compared with placebo reduced the 
risk of healthcare-associated diarrhea.25 
Administration of two other probiotics (L. reuteri 
DSM 17938 and L. delbrueckii H2B20) was 
ineffective.25 Currently there is sufficient evidence 
showing that LGG administrated in a dose of at least 
109 CFU/day during a hospital stay can significantly 
reduce the risk for nosocomial diarrhea in a regular 
Table 1. Probiotics and prevention of acute gastroenteritis 
Author (year)ref Strain Incidence acute gastroenteritis p 
  Probiotic Placebo  
Chouraqui (2004) 7 B lactis Bb 12 28.3 % 38.7 % NS 
Hojsaka (2016) 8 B animaliss Bb 12 64.4% 61.3% NS 
Sazawal (2010) 9 B. lactis HN019 
(+ prebiotic) 
5.26 ep 5.44 ep NS 
Laursen (2017) 10 B. lactis BB12 
L. rhamnosus GG 
64% 56% 0.14 
Bocqueta (2013) 11 B. lactis BB12 
 
4.5 + 3.0 ep 4.9b + 3.2 ep 0.18 
Oberhelman (1999) 12 L. rhamnosus GG 5.21 6.02 0.028 
Pedone (2000) 16 L. casei DN-114 001 15.9% 22%c 0.03 
Weizman (2005) 17 L. reuteri ATC 55730 
B. Lactis BB12 
0.02 ep 
0.13 ep 
0.31 ep <0.001 
acommon infections reported (not only acute gastroenteritis)  
bprebiotics group 
cyoghurt  
ep=episodes  
B=Bifidobacterium  
L.=Lactobacillus 
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pediatric ward.26 So far, research has found no 
evidence of effectiveness of L. reuteri DSM 17938 
in preventing nosocomial diarrhea in children.27,28 
Based on currently available evidence, there is 
evidence to recommend LGG when the use of 
probiotics for preventing nosocomial diarrhea in 
children is considered, as recommended by the 
Working Group on Probiotics from the European 
Society of Paediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHAN).29,30 
Antibiotic associated diarrhea 
The prevention of antibiotic associated diarrhea 
(AAD) has been the subject of many investigations, 
both in children and adults. Most commonly used 
probiotics are LGG, L. acidophilus, L. casei, B. ssp, 
Streptococcus ssp, and the yeast Saccharomyces 
boulardii (S. boulardii). In general, most of these 
trials do show clear evidence of efficacy, with the 
two most effective strains being LGG and S. 
boulardii. Evidence is also emerging on the 
importance of the dose in reducing the incidence of 
this type of diarrhea, as well as the incidence of 
Clostridium difficile (C. difficile)-associated post-
antibiotic diarrhea.31 A yogurt combination of LGG, 
L. acidophilus and B. BB12 was reported to be an 
effective method to reduce the incidence of AAD in 
children (Table 3).32 L. plantarum DSM9843 was 
not better than placebo regarding the incidence of 
loose/watery stools, mean number of loose/watery 
stools, or the incidence of abdominal symptoms 
during antibiotic administration.33 L. reuteri DSM 
17938 was not effective in the prevention of diarrhea 
or AAD in children.34 S. boulardii was shown to 
prevent AAD in children hospitalized because of a 
respiratory tract infection, and to be effective in the 
treatment of AAD in children that developed it in the 
placebo group.35  
According to a review, moderate-quality 
evidence suggests that probiotics are associated with 
lower rates of AAD in children (aged 1 month to 18 
years) without an increase in adverse events.36 A 
Cochrane systematic review, analyzing data from 23 
studies (3938 participants), estimates a pooled 
probiotic effect (RR 0.46; 95% CI: 0.35-0.61) with 
a number needed to treat of 10 [37]. A post hoc 
subgroup analysis to explore heterogeneity indicated 
that probiotics are effective among trials with a C. 
difficile associated diarrhea baseline risk >5%. The 
weakness of this kind of meta-analysis is that all 
probiotic strains are grouped together, while some 
strains might be more effective than others. Among 
the various probiotics evaluated, LGG or S. 
boulardii at 5–40 x 109 CFU/day may be appropriate 
given the modest number needed to treat and the 
likelihood that adverse events are very rare.33 In a 
meta-analysis, LGG was reported to be effective in 
preventing AAD in children and adults treated with 
antibiotics for any reason, although with a moderate 
to low quality of evidence.38 Moderate quality 
evidence suggests that probiotics are associated with 
a lower risk of C. difficile infection and very-low 
quality evidence suggests that probiotics are 
associated with fewer adverse events than either 
placebo or no treatment.39 ESPGHAN recommends 
that, if the use of probiotics to prevent AAD is 
considered because of the existence of risk factors 
such as class of antibiotic(s), duration of antibiotic 
treatment, age, need for hospitalization, 
comorbidities, or previous episodes of AAD 
diarrhea, LGG (moderate Quality of Evidence 
Table 2. Probiotics and prevention of nosocomial diarrhea 
Author (year) ref Strains Incidence nosocomial diarrhea p 
  Probiotic Placebo  
Saavedra (1994) 20 B. bifidum 
Str.  thermophilus 
7% 31% 0.035 
Hojsak (2015) 21 B.  animalis BB12 8.0% 6.0% NS 
Szajewska (2001) 22 L. rhamnosus GG 6.7% 33.3% 0.002 
Mastretta (2002) 23 L. rhamnosus GG 25.4% 30.2% 0.432 
Bruzzese (2016) 24 L. rhamnosus GG 9% 33% 0.016 
Urbańska (2016) 27 L. reuteri DSM 17938 6.4% 7.7% NS 
Wanke (2012) 28 L. reuteri DSM 17938 33% 31% NS 
B=Bifidobacterium, Str=Streptococcus, L=Lactobacillus 
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(QoE), strong recommendation) or S. boulardii 
(moderate QoE, strong recommendation) should be 
used.40 LGG survival is sensitive to penicillin which 
might make this probiotic ineffective in when this 
type of antibiotic is in use.41 
A Cochrane analysis included 33 studies 
with 6352 participants, assessing the following 
probiotics: Bacillus spp., Bifidobacterium spp., 
Clostridium butyricum, Lactobacilli spp., 
Lactococcus spp., Leuconostoc cremoris, 
Saccharomyces spp., or Streptococcus spp., alone or 
in combination.42 The overall evidence suggests a 
moderate protective effect of probiotics for 
preventing AAD. The number needed to treat for an 
additional beneficial outcome was 9 (95% CI 7 to 
13).42BB If only studies with high doses of probiotics 
are considered (≥ 5 billion CFUs per day), the 
number needed to treat for an additional beneficial 
outcome to prevent one case of diarrhea is reduced 
to 6 (95% CI 5 to 9).42  
If the use of probiotics to prevent C. difficile-
associated diarrhea is considered, S. boulardii (low 
QoE, conditional recommendation) is 
recommended.30,40 Other strains or combinations of 
strains have been tested for this purpose, but 
evidence for efficacy is insufficient.40 Despite the 
need for further research, hospitalized patients, 
particularly those at high risk of C. difficile 
associated diarrhea, should be informed of the 
potential benefits and harms of probiotics.30 S. 
boulardii, and more recently fecal microbiota 
transplantation have become valid forms of 
prevention and/or therapy for C. difficile colitis.43 
Analysis has shown that the potential for using S. 
boulardii as AAD prophylactic treatment in adult 
hospitalized patients in Belgium would, based on 
831,655 hospitalizations with antibiotic 
administration in 2014, result in a € 50.3 cost saving 
per patient.44  Generalized use of S. boulardii in 
hospitalized adults treated with antibiotics could 
result in total annual savings up to € 41.8 million for 
the Belgian health care.44 There are no data on the 
economic impact of prophylactic probiotic 
administration to prevent AAD in children. 
 
Probiotics and prevention of infantile colic 
Infantile colic describes excessive crying of 
unknown cause in otherwise well infants.45 The 
incidence is approximately 10% to 40% of infants 
worldwide and is similar among formula-fed and 
breast-fed infants. Proposed causes include 
alterations in fecal microbiota, allergy to cow's milk 
protein, lactose malabsorption, gastrointestinal 
immaturity or inflammation, increased serotonin 
secretion, poor feeding technique, and maternal 
smoking or nicotine replacement therapy.46 The vast 
majority of published articles concerning treatment 
of infantile colic have evaluated probiotics as a 
therapeutic tool and have shown that L. reuteri DSM 
17938 was effective in reducing infantile colic 
mainly in breastfed infants.47 Six studies included 
for subgroup meta-analysis on probiotic treatment, 
notably L. reuteri, demonstrated that probiotics 
appear an effective treatment, with an overall mean 
difference in crying time at day 21 of -55.8 min/day 
(95% CI -64.4 to -47.3, P = 0.001).48 
Table 3. Probiotics and prevention of antibiotic associated diarrhea 
Author (year) ref Strains AAD p 
  Probiotic Placebo  
Fox (2015) 32 L. rhamnosus GG 
B. lactis Bb-12 
L. acidophilus La-5a 
0 % 18% 0.025 
Olek (2017) 33 L. plantarum DSM9843 39% 44.5% NS 
Kołodziej (2018) 34 L. reuteri DSM 17938 6.5% 11.4% NS 
Shan (2013) 35 S. boulardii 4.3 % 19.4% <0.001 
aboth probiotic and placebo groups received yoghurt;  
AAD=Antibiotic Associated Diarrhea 
L.=Lactobacillus 
B.=Bifidobacterium 
S.=Saccharomyces 
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Only limited data are available regarding the 
use of probiotics in the prevention of this common 
entity in infancy, since only two clinical studies have 
been published. The first trial included 468 infants, 
breastfed as well as formula-fed, revealing that 
compared with placebo, the daily administration of 
L. reuteri DSM 17938, from day 3 for 90 days, 
resulted in a significant reduction in crying time by 
approximately 51 minutes per day at 1 month, and 
by 33 minutes per day at 3 months. There were also 
significantly less emergency room visits, lost 
parental working days and use of additional 
medications in infants who received the probiotic 
agent. A cost-benefit analysis revealed significant 
savings as well.49 Although almost half of the infants 
were breast fed, results are not given separately for 
breast or formula fed infants. Preventive 
administration of L. reuteri was shown to reduce the 
number of consultations because of colic, and to 
reduce health care cost, both for the family (88 €) 
and for the community (104 €).50,51 The second 
study was based on a secondary analysis of data 
from a trial of LGG supplementation, for the first 6 
months of life in 184 infants. No significant 
differences were found between the infants exposed 
to early LGG supplementation, versus infants 
exposed to the control intervention.52 In a third small 
study, with poorly-defined methods, preventive 
administration of B. breve B632 and BR03 resulted 
in a mean duration of crying of 12.14 minutes on 
average in the probiotics group and of 46.65 minutes 
in the placebo group during the third month of 
supplementation. However, no significant 
differences were noticed during the first or second 
months of supplementation [53]. In view of these 
conflicting results, further controlled large-scale 
strain-specific trials are warranted. L. reuteri 
DSM17938 has been recommended at a dose of 108 
CFU once daily as preventive strategy of infantile 
colic (level I evidence).30  
A Cochrane review including six studies 
with 1886 participants, compared probiotics with 
placebo: two studies examined L. reuteri DSM 
17938, two examined multi-strain probiotics, one 
examined L.  rhamnosus, and one examined 
L.paracasei and B.animalis.54 No clear evidence 
could be found that probiotics are more effective 
than placebo at preventing infantile colic; however, 
daily crying time appeared to reduce with probiotic 
use compared to placebo.54 In summary, although 
there is insufficient evidence for a recommendation, 
available data suggest that specific probiotics strains 
such as L. reuteri DSM 17938 may prevent infantile 
colic in some infants. Since L reuteri administration 
is reported to be safe, the major issue of concern is 
the cost-benefit. 
 
Probiotics and prevention of necrotizing 
enterocolitis (NEC) 
 
NEC is in some countries among the most common 
and devastating diseases in neonates and thus has 
become a priority for research.55 The 
pathophysiology of classic NEC is incompletely 
understood, but epidemiologic observations strongly 
suggest a multifactorial cause.56 Inappropriate initial 
microbial colonization in preterm infants is 
considered to be an important risk factor for NEC,57 
particularly since NEC does not occur until at least 
8 to 10 days postpartum, at a time when anaerobic 
bacteria have colonized the gut. Furthermore, 
experimental NEC does not occur in germ-free 
animals,58 and infants with NEC frequently have 
concomitant bacteraemia and endotoxemia.59 C. 
perfringens is associated with NEC from the first 
meconium till just before NEC onset.60 In contrast, 
post-meconium, increased numbers of staphylococci 
were negatively associated with NEC.60 
L. reuteri DSM 17938 administered to 
preterm infants was shown to be safe and to reduce 
significantly feeding intolerance.61 No significant 
differences were found for any other secondary 
outcomes such as necrotizing enterocolitis (NEC), 
hospital stay, sepsis and diarrhea.  
In contrast, a meta-analysis concluded that 
bifidobacteria administration reduced the relative 
risk of developing NEC (RR 0.38, 95% CI 0.25-
0.58; P < 0.00001) or death (RR 0.74, 95% CI 0.60-
0.92; P = 0.006), but no significant difference in the 
incidence of sepsis was found (RR 0.87, 95% CI 
0.73-1.03; P = 0.11).62 In a retrospective 
observational study, the incidence of NEC in 640 
very low birth weight infants with a median 
gestational age of 28.7 weeks that were given LGG 
was 12 % compared to 10.2 % before the 
implementation of the probiotic administration.63 
The conclusion of this trial was that LGG increased 
the risk to develop NEC.63 However, another group 
 World.Nutr.Journal | 9  
came to an opposite conclusion with a comparable 
protocol in a retrospective observational study 
performed in a resource limited setting: LGG 
reduced significantly NEC ≥ Stage II and the 
composite outcome of NEC ≥ Stage II/mortality in 
preterm infants.64 According to a strain-specific 
network meta-analysis, only 3 of 25 studied 
probiotic treatment combinations (the combination 
of B.bifidum NCDO 1453 and L. acidophilus NCDO 
1748 (based on 2 studies with 494 infants); the 
combination of B. bifidum, B. infantis, B. longum, 
and L. acidophilus (based on 1 study with 186 
infants); and the combination of B. infantis, L. 
acidophilus, L. casei, L. plantarum, L. rhamnosus, 
and S. thermophilus altogether (based on 1 study 
with 150 infants) showed significant reduction in 
mortality.64 Seven treatments reduced NEC 
incidence (B.lactis Bb-12 or B94, based on 5 trials 
with 828 infants; L. reuteri ATCC 55730 or DSM 
17938, based on 4 studies with 1459 infants; L. GG, 
based on 6 studies with 1507 infants); the 
combination of B. bifidum, B. infantis, B. longum, 
and L. acidophilus, based on 2 studies with 247 
infants; the combination of B. infantis ATCC 15697 
and L. acidophilus ATCC 4356, based on one study 
with 367 infants; the combination of B. infantis Bb-
02, B. lactis Bb-12, and S. thermophilus TH-4, based 
on 2 studies with 1244 infants; and the combination 
of B.longum 35624 and LGG, based on 2 studies 
with 285 infants, 2 reduced late-onset sepsis 
(combination of B. bifidum, B. infantis, B. longum, 
and L. acidophilus (based on 2 studies with 247 
infants); for the combination of B. longum R00175, 
L. helveticus R0052, L. rhamnosus R0011, and S. 
Boulardii CNCM I-1079, based on 3 studies with 
241 infants, and 3 reduced time until full enteral 
feeding (L. reuteri ATCC 55730 or DSM 17938, 
based on 3 studies with 626 infants); for the 
combination of B. bifidum, B. infantis, B. longum, 
and L.acidophilus, based on 2 studies with 247 
infants; and for the combination of B. longum 
BB536 and LGG, based on 1 study with 94 infants.64 
There was no clear overlap of strains, which were 
effective on multiple outcome domains.64 The 
network meta-analysis showed efficacy in reducing 
mortality and morbidity in only a minority of the 
studied strains or combinations. This may be due to 
an inadequate number or size of randomized 
controlled trials, or due to a true lack of effect for 
certain species.65 The importance of strain 
specificity and a demonstration of safety is 
highlighted since a specific product (InfloranTM) was 
reported to increase the incidence of NEC.66 Further 
large and adequately powered randomized 
controlled trials using strains with the greatest 
apparent efficacy will be needed to define more 
precisely optimal treatment strategies. 
Compared to formula feeding, breastmilk 
protects for NEC. However, both in breast and 
formula fed preterms probiotics seem to be one of 
the most significant advances in NEC prevention at 
present because of the significant range of beneficial 
effects at various levels of gut function and defense 
mechanisms.4,30 While some authors published 
strong evidence to support general effects of 
probiotics as a group, rather than focusing on strain 
specific effects, others do question this approach and 
conclude that there is insufficient evidence to guide 
the selection of the most effective strains.4-6 
 
Probiotics and prevention of regurgitation 
 
Regurgitation is one of the most common functional 
gastrointestinal disorders in infants, with a 
significant impact on quality of life of the infants 
and the family.67,68 Administration of L. reuteri 
DSM 17938 prevented regurgitation episodes during 
the first month of life in exclusively breastfed 
infants, when compared to historic controls.69,70 
Prophylactic use of L. reuteri DSM 17938 from birth 
to 3 months resulted in a decreased number of 
episodes of regurgitations per day, compared to no 
probiotic (2.9 vs 4.6; P < .01).49 This finding is likely 
to be related to the faster gastric emptying induced 
by the probiotic.70 A synbiotic infant formula, 
supplemented with B. lactis  and fructo-
oligosaccharides, with lactose and a whey/casein 
60/40 protein ratio was tested in 280 infants over 3 
months and resulted in a lower incidence of daily 
regurgitation (10.9% of all infants) compared to the 
median prevalence for a similar age according to 
historic data from literature (median value of 
26.7%).71 Some probiotic strains may enhance 
gastric emptying and therefore have a beneficial 
effect on functional gastro-intestinal symptoms of 
the esophagus and stomach.  
L. reuteri DSM 17938 decreased dysbiosis in 
children treated with proton pump inhibitors.72 After 
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12 weeks of treatment with a proton pump inhibitor, 
dysbiosis was diagnosed according to the results of 
a glucose hydrogen breath test in 56.2% of the 
children in the placebo group, compared to 6.2% of 
the children in the probiotic group (P < 0.001).72 
Bacterial overgrowth was detected in 5% of 
controls, which is similar to the group treated with 
L. reuteri and proton pump inhibitors.72  
There is insufficient evidence from literature 
to recommend routine administration of some 
specific probiotic strains for the prevention of 
regurgitation. However, no study suggested that 
probiotics may increase the risk for regurgitation. L. 
reuteri DSM 17938 may decrease the adverse 
effects of proton pump inhibitors on the GI 
microbiota.  
Probiotics and prevention of constipation 
A meta-analysis concluded that there is insufficient 
evidence to recommend pre-, pro- or synbiotics in 
the treatment of children with functional 
constipation.73 Another meta-analysis showed that 
some probiotic strains increase stool frequency in 
Asian children.74 A synbiotic infant formula, 
supplemented with B. lactis and fructo-
oligosaccharides, was tested in 280 infants over a 3-
month period and showed a lower incidence of 
constipation (3.2%) than the incidence reported in 
literature (7.8%).71 L. reuteri DSM 17938 
administration resulted in a statistically significant 
increase in mean number of defecations per day 
compared to placebo in infants (4.2 vs 3.6; 
P < .01).48 Although there is insufficient evidence 
for a recommendation, there are some data that 
preventive administration of probiotics to infants 
may increase the number of defecations per day.  
Probiotics and prevention of Helicobacter pylori 
Lactobacilli, as an adjunct to triple therapy, 
increases Helicobacter pylori eradication rates and 
reduces the incidence of therapy-related diarrhea in 
children.75 According a meta-analysis of data 
obtained with S. boulardii in 11 RCTs (2200 
participants, among them 330 children), the yeast 
probiotic is likely to increase the eradication rate by 
about 10 percent and to decrease the adverse effects 
of the eradication therapy.76 A meta-analysis of 5 
studies (434 participants), concluded that the 
lactobacilli strains differed among studies: L. 
acidophilus and L. rhamnosus, L. reuteri, L. casei, 
LGG, and compound lactobacillus but detailed 
information was rarely provided of the strains 
used.75 However, there are no data on the prevention 
of Helicobacter pylori infection by the 
administration of probiotics.  
Probiotics and small bowel bacterial overgrowth 
There are a few studies in adults showing that the 
clinical consequence of small intestinal bacterial 
overgrowth can be treated effectively by 
administration of probiotics.77 However, L. 
rhamnosus R0011 (1.9×109 CFU) and L. 
acidophilus R0052 (0.1×109 CFU) failed to decrease 
the incidence of small bowel bacterial overgrowth in 
children treated with omeprazole.78 However, we 
could not find any information on the use of 
probiotics in the prevention of this condition.  
Probiotics and prevention of irritable bowel 
syndrome 
 
Although there are some data that some specific 
strains alleviate pain in children with irritable 
bowel syndrome,79,80 we could not find information 
on prevention. 
 
Probiotics and prevention of inflammatory bowel 
disease 
No randomized controlled trials were found 
evaluating if preventive administration of probiotics 
may decrease the number of flares of inflammatory 
bowel disease in children. 
 
Conclusion 
 
The authors of this review strongly believe in strain 
and product specificity in probiotic research. 
Extrapolation from studied strains to unstudied 
strains and products could lead to erroneous 
conclusions. Clinical trials using commercialized 
products should give attention to influencing factors 
such as product quality and shelf life.  
The ability to impact the microbiome with 
probiotics is an interesting approach in the 
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prevention of GI diseases, but studies on probiotic 
administration to prevent GI disorders are limited. 
Most studies focus on treatment and not prevention. 
The studies available on prevention of gastro-
intestinal diseases in children focus on infectious, 
nosocomial and antibiotic-associated diarrhea or 
NEC, and there are some studies on infantile colic.  
Studies on the prevention of NEC differ in design 
and strains tested.  Partly for this reason, there is no 
consensus to recommend the routine administration 
of probiotics to preterm infants to prevent NEC. The 
possibility of serious adverse effects in preterm 
infants should also be considered in continuing 
research.  
There is also no consensus if probiotics 
should be administered routinely to normal infants 
to prevent acute gastroenteritis, AAD and infantile 
colic. The best evidence for benefit regards B. lactis 
(for acute gastroenteritis), S. boulardii and LGG (for 
AAD) and L. reuteri DSM 17938 for infantile colic, 
for regurgitation and stool composition. Despite the 
lack of evidence, many infant formulae do contain 
probiotics and thus many infants are exposed to 
daily intake of probiotic strains. Research is 
inadequate to judge whether or not to recommend 
the use of these products in artificially fed infants.  
Overall there are insufficient data to 
recommend routine administration of probiotics to 
prevent GI disorders. However, one could also 
consider that preventive probiotic administration is 
unlikely to be harmful or cause adverse effects 
except possibly in very vulnerable infants such as 
prematures and that preventive administration of 
probiotics can be considered because of the safety 
profile even if the evidence suggesting benefit is 
limited so far. 
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